PURPOSE: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy. Current recommendations include offering regional lymph node evaluation by either sentinel lymph node biopsy (SLNB) or complete lymph node dissection (CLND) to all patients with MCC; however, we hypothesized a cohort of low-risk patients may exist for whom regional nodal metastasis would be unlikely. METHODS: A retrospective review of the Department of Veterans Affairs national health care database was performed. Patients undergoing resection of primary MCC were identified; and demographic, medical, and social history; tumor characteristics; nodal status; and recurrence events were recorded. RESULTS: Between 1995 and 2006, 346 patients were diagnosed with MCC. Of these, 213 underwent resection of the primary lesion and evaluation of the draining lymph node basin. Fifty-four patients (25%) had tumors < or = 1.0 cm in diameter. Average tumor diameter was 0.7 cm, and 63% were located on the head or neck. Only two patients (4%) with tumors < or = 1.0 cm had regional lymph node metastasis, compared with 51 (24%) of 213 patients with tumors more than 1.0 cm (P < .0001). Both patients had clinically evident nodal disease at presentation and underwent CLND. Both have remained recurrence-free for 40 months. Thirteen (25%) of 51 patients with nodal metastasis and tumors more than 1 cm had occult nodal metastasis. CONCLUSION: In this series, patients with MCC < or = 1.0 cm were unlikely to have regional lymph node metastasis, suggesting that regional nodal evaluation may reasonably be avoided in these patients. However, these data support SLNB for MCC more than 1 cm in diameter.
PURPOSE:Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy. Current recommendations include offering regional lymph node evaluation by either sentinel lymph node biopsy (SLNB) or complete lymph node dissection (CLND) to all patients with MCC; however, we hypothesized a cohort of low-risk patients may exist for whom regional nodal metastasis would be unlikely. METHODS: A retrospective review of the Department of Veterans Affairs national health care database was performed. Patients undergoing resection of primary MCC were identified; and demographic, medical, and social history; tumor characteristics; nodal status; and recurrence events were recorded. RESULTS: Between 1995 and 2006, 346 patients were diagnosed with MCC. Of these, 213 underwent resection of the primary lesion and evaluation of the draining lymph node basin. Fifty-four patients (25%) had tumors < or = 1.0 cm in diameter. Average tumor diameter was 0.7 cm, and 63% were located on the head or neck. Only two patients (4%) with tumors < or = 1.0 cm had regional lymph node metastasis, compared with 51 (24%) of 213 patients with tumors more than 1.0 cm (P < .0001). Both patients had clinically evident nodal disease at presentation and underwent CLND. Both have remained recurrence-free for 40 months. Thirteen (25%) of 51 patients with nodal metastasis and tumors more than 1 cm had occult nodal metastasis. CONCLUSION: In this series, patients with MCC < or = 1.0 cm were unlikely to have regional lymph node metastasis, suggesting that regional nodal evaluation may reasonably be avoided in these patients. However, these data support SLNB for MCC more than 1 cm in diameter.
Authors: J Ortin-Perez; M C van Rijk; R A Valdes-Olmos; S Vidal-Sicart; O E Nieweg; A Vilalta; B B R Kroon; F Pons Journal: Eur J Surg Oncol Date: 2006-10-17 Impact factor: 4.424
Authors: Franz O Smith; Binglin Yue; Suroosh S Marzban; Brooke L Walls; Michael Carr; Ryan S Jackson; Christopher A Puleo; Tapan Padhya; C Wayne Cruse; Ricardo J Gonzalez; Amod A Sarnaik; Michael J Schell; Ronald C DeConti; Jane L Messina; Vernon K Sondak; Jonathan S Zager Journal: Cancer Date: 2015-06-02 Impact factor: 6.860
Authors: Jennifer L Schwartz; Kent A Griffith; Lori Lowe; Sandra L Wong; Scott A McLean; Douglas R Fullen; Christopher D Lao; James A Hayman; Carol R Bradford; Riley S Rees; Timothy M Johnson; Christopher K Bichakjian Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 44.544
Authors: Ryan C Fields; Klaus J Busam; Joanne F Chou; Katherine S Panageas; Melissa P Pulitzer; Dennis H Kraus; Mary S Brady; Daniel G Coit Journal: Ann Surg Oncol Date: 2011-03-24 Impact factor: 5.344
Authors: Jayasri G Iyer; Barry E Storer; Kelly G Paulson; Bianca Lemos; Jerri Linn Phillips; Christopher K Bichakjian; Nathalie Zeitouni; Jeffrey E Gershenwald; Vernon Sondak; Clark C Otley; Siegrid S Yu; Timothy M Johnson; Nanette J Liegeois; David Byrd; Arthur Sober; Paul Nghiem Journal: J Am Acad Dermatol Date: 2014-02-09 Impact factor: 11.527
Authors: Jürgen C Becker; Andreas Stang; James A DeCaprio; Lorenzo Cerroni; Celeste Lebbé; Michael Veness; Paul Nghiem Journal: Nat Rev Dis Primers Date: 2017-10-26 Impact factor: 52.329
Authors: M Loyo; J Schussel; E Colantuoni; J Califano; M Brait; S Kang; W M Koch; D Sidransky; W H Westra; J M Taube Journal: Br J Cancer Date: 2012-03-13 Impact factor: 7.640